Loading
A phase 2 trial of Evorpacept, Trastuzumab, Capecitabine, Eribulin, Gemcitabine and Vinorelbine in HER2-positive breast cancer, run by ALX Oncology Inc., now recruiting.
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer is a phase 2 interventional study registered as NCT07007559 by ALX Oncology Inc., with 120 participants planned, started 2025-12-10 and due to reach its primary completion in 2027-12. Interventions recorded: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin and Gemcitabine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine and the tag pipeline.
Shares Trastuzumab, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.